Compare AbbVie Inc (ABBV) vs Capri Holdings Ltd (CPRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Capri Holdings Ltd — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while Capri Holdings Ltd trades at $17.68 (market cap $2.23B). The key difference: AbbVie Inc is far larger — about 201.8× Capri Holdings Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| ABBV | CPRI | |
|---|---|---|
Market Cap | $449.91B | $2.23B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $27.66 |
52-Week Low | $184.85 | $16.79 |
Enterprise Value | $513.38B | $3.51B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
CPRI trades at $19.41, up 2.37% today, amid mixed signals with bearish technical indicators but improving fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $0.22 versus $0.118, while revenue trends show stabilization after declines. The company's net income margin improved to 3.94% for 2026, though 2025 saw a significant loss. Analyst consensus is mixed with 44% buy ratings and a $23.43 price target, suggesting potential upside from current levels.
The outlook hinges on CPRI's turnaround execution, with risks including luxury demand volatility and high debt. Positive catalysts include projected FY2027 growth and cost management efforts. Investors should weigh the attractive P/S ratio of 0.65 against ongoing operational challenges and insider selling noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →
